Healthcare Services

Fecal Transplant Therapy Market: Trends and Expansion Potential

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Fecal Transplant Therapy Market Progress Between 2026 And 2030?

The fecal transplant therapy market size has experienced robust growth in recent years. This market is projected to expand from $2.15 billion in 2025 to $2.28 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion can be linked to factors such as documented efficacy in recurrent cdi treatment, rising hospital awareness of microbiome therapies, the broadening of gastroenterology specialty services, the presence of basic stool preparation technologies, and initial-stage clinical trials.

The market for fecal transplant therapy is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. Key drivers of this growth during the forecast period include the expanding range of disease indications, a heightened need for standardized and regulated products, the increased availability of outpatient Fecal Microbiota Transplant (FMT) procedures, escalating investments in microbiome-based therapies, and innovations in automated stool processing systems. Significant trends expected over the forecast period encompass a greater clinical acceptance of stool-based treatments, the progressing development of capsule and suspension forms, an increasing focus on neurological and metabolic applications, the proliferation of in-hospital FMT initiatives, and a stronger focus on ensuring safety and standardization.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/fecal-transplant-therapy-global-market-report

What Major Factors Are Driving The Fecal Transplant Therapy Market Forward?

The rising occurrence of inflammatory bowel disease is anticipated to boost the expansion of fecal transplant therapy markets in the future. Inflammatory bowel disease (IBD) refers to persistent inflammation affecting the digestive system, encompassing conditions like Crohn’s disease and ulcerative colitis. This increase in IBD incidents stems from greater intake of highly processed foods, regular or improper antibiotic usage, enhanced sanitation, and diminished childhood exposure to infectious elements. Fecal transplant therapy seeks to re-establish a balanced gut microbiota, thereby aiding in reducing inflammation and alleviating symptoms for individuals with inflammatory bowel disease, potentially impacting its treatment and course. As an illustration, in June 2023, according to Crohn’s and Colitis Canada, a Canada-based non-profit organization, there will be 470,000 inflammatory bowel disease (IBD) sufferers in Canada by 2035, an increase from an estimated 322,600 in 2023. Consequently, the growing commonness of inflammatory bowel disease is fueling the expansion of the fecal transplant therapy market.

How Is The Fecal Transplant Therapy Market Organized By Segment Classification?

The fecal transplant therapy market covered in this report is segmented –

1) By Procedure: Fecal Enema, Fecal Bacteriotherapy, Stool Transplant, Human Probiotic Infusion, Fecal Transfusion

2) By Disease: Clostridium Difficile Infection, Autism, Obesity, Parkinson’s Disease (PD), Diabetes Mellitus, Other Diseases

3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Fecal Enema: Retention Enema, Cleansing Enema, Retention-Based Fecal Transplants, Home Administration Kits

2) By Fecal Bacteriotherapy: Suspension-Based Bacteriotherapy, Capsule Formulations, Customized Bacterial Preparations, Single Strain vs. Multi-Strain Products

3) By Stool Transplant: Direct Stool Transplant Procedures, Stool Suspension Transplant, Stool Capsule Transplant, Automated Stool Preparation Systems

4) By Human Probiotic Infusion: Single-Strain Probiotic Infusions, Multi-Strain Probiotic Infusions, Probiotic Blends With Prebiotics, Infusion Kits for Healthcare Providers

5) By Fecal Transfusion: Intravenous Fecal Transfusion, Transfusion via Gastrostomy Tube, Pre-Packaged Fecal Transfusion Solutions, Fecal Transfusion For Research Purposes

Which Trends Are Impacting The Progress Of The Fecal Transplant Therapy Market?

Leading companies in the fecal transplant therapy market are prioritizing the creation of innovative treatments, such as oral capsule versions of fecal microbiota transplantation (FMT) therapy, to boost patient compliance and widen the therapy’s reach. This pill form of fecal microbiota transplantation (FMT) therapy contains encapsulated live bacteria derived from donor feces, intended for oral consumption. Its goal is to restore beneficial gut bacteria and enhance intestinal health. For example, in April 2023, Seres Therapeutics Inc., a US-based biotechnology company, and Nestlé Health Science S.A., a Switzerland-based healthcare company, introduced VOWST. Supplied as capsules, it presents a convenient and less invasive treatment alternative for preventing recurrent clostridioides difficile infection (rCDI) in adults who have completed antibacterial treatment. Unlike traditional fecal microbiota transplantation (FMT), which involves transferring whole stools, VOWST employs live bacterial spores of multiple Firmicute species, sourced from the fecal microbiota of healthy human donors, with the aim of restoring the gut microbiome.

Who Are The Industry Participants Involved In The Fecal Transplant Therapy Market?

Major companies operating in the fecal transplant therapy market are Mayo Clinic, Mount Sinai Health System Inc., Northwestern Medicine, NYU Langone Health, Michigan Medicine, UCLA Health, Duke University Health System Inc., Stanford Health Care, Ferring Pharmaceuticals, Cincinnati Children’s Hospital Medical Center, Emory Healthcare, Cambridge University Hospitals NHS Foundation Trust, Hamilton Health Sciences Corporation, Brigham and Women’s Faulkner Hospital Inc., Rebiotix Inc., Seres Therapeutics Inc., UPMC Hillman Cancer Center, OpenBiome, Center for Digestive Disease, BiomeBank Incorporated, The Regents of the University of California

Get The Full Fecal Transplant Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/fecal-transplant-therapy-global-market-report

Which Region Leads The Fecal Transplant Therapy Market In Terms Of Market Share?

North America was the largest region in the fecal transplant therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fecal transplant therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Fecal Transplant Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/fecal-transplant-therapy-global-market-report

Browse Through More Reports Similar to the Global Fecal Transplant Therapy Market 2026, By The Business Research Company

Stem Cells Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/stem-cells-therapy-global-market-report

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795